News

A 60-year-old man with atypical hemolytic uremic syndrome (aHUS) was successfully treated with Soliris (eculizumab) using a personalized dosing regimen based on clinical responses, according to a recent case study. Clinicians lowered the dose of the medication in parallel with clinical improvements and eventually discontinued treatment instead of…

Changes in platelet counts over the first two weeks on Ultomiris (ravulizumab-cwvz) in people with atypical hemolytic uremic syndrome (aHUS) may help predict the patients’ long-term response to such treatment, according to a new study. An analysis found that patients’ early platelet responses were linked to kidney improvements at…

Bone abnormalities were reported in two teenage girls who were on long-term treatment with Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) associated with a deficiency of the complement factor H (FH). Clinicians are unsure whether these previously undescribed bone abnormalities, including pain, deformities, and joint swelling, were…

Initial treatment with the drug Soliris (eculizumab) and immunosuppressive therapies was safe and effective for four children with severe atypical hemolytic uremic syndrome (aHUS) who had self-reactive antibodies against the complement factor H (FH). That’s according to a study from Argentina, which reported that all of the children…

Genetic testing may allow for the timely use of anti-complement therapy for atypical hemolytic uremic syndrome (aHUS), even if an infection with Shiga toxin-producing Escherichia coli (STEC), a trigger of the typical form of the disease, is present and initially upstages the correct diagnosis of aHUS. In a…

The National Organization for Rare Disorders (NORD) is offering patient assistance programs specifically for people in the U.S. with atypical hemolytic uremic syndrome (aHUS), to help cover out-of-pocket medical costs and emergency nonmedical expenses in their daily lives. These initiatives come under NORD’s RareCare program, which was…

Mutations in the Wilms’ tumor 1 (WT1) gene, known to cause a rare kidney disorder called Denys-Drash syndrome, were found in four children who had symptoms of atypical hemolytic uremic syndrome (aHUS), according to recent case series study. “To our knowledge, this is the first report of a series…

The first case of a patient with both atypical hemolytic uremic syndrome (aHUS) and Brugada syndrome, an irregular heartbeat disorder that increases the risk of sudden death, was described in a report involving a 15-year-old girl in Oman. The researchers noted that “atypical HUS is a variable disease that…

Hip surgery triggered atypical hemolytic uremic syndrome (aHUS) in a 49-year-old woman, who was successfully treated with plasma exchange, which is a blood-cleaning procedure, and kidney replacement therapy, according to a case study in India. A prompt diagnosis and multidisciplinary collaboration, as well as early and aggressive treatment of…

This year’s aHUS Awareness Day, Sept. 24, will highlight mental health issues important to people with atypical hemolytic uremic syndrome (aHUS) and their families. The annual event is being organized by the aHUS Alliance, an international umbrella organization that comprises patient groups and aHUS advocates to support patients,…